SOFTMEDX (00648) announced its interim results, with a net profit of HK$4.648 million, a year-on-year increase of 38.62%.

date
20:37 10/08/2026
avatar
GMT Eight
Beijing Jiukang Therapy (00648) announced its mid-term performance for 2026, with revenue of HKD 34.075 million, a year-on-year decrease of 4.74%; net profit of HKD 4.648 million, a year-on-year increase of 38.62%; and earnings per share of HKD 0.044.
SOFTMEDX (00648) announced its mid-term results for 2026, with revenue of HKD 34.075 million, a decrease of 4.74% year-on-year; net profit of HKD 4.648 million, an increase of 38.62% year-on-year; and earnings per share of HKD 0.044. The announcement stated that the increase in profit was mainly due to the following factors: a reduction in administrative expenses and the absence of losses from fair value changes of financial assets measured at fair value through profit or loss.